US EditionShuttle Pharma Targets Prostate Cancer With PSMA Ligand Breakthrough
Summary by WealthyVC
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Shuttle Pharma Targets Prostate Cancer With PSMA Ligand Breakthrough
Shuttle Pharmaceuticals (NASDAQ: SHPH) is advancing its mission to revolutionize prostate cancer treatment. On April 10, 2025, the company announced the filing of a pivotal provisional patent application with the United States Patent and Trademark Office. The application, titled “PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy,” marks a major milestone in the firm’s push to develop advanced diagnostic and therapeutic tools f…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
